medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2022, Number 6

<< Back Next >>

Rev Mex Urol 2022; 82 (6)

Behavior of MV140 vaccine to prevent recurrent urinary tract infections in patients with metabolic syndrome and smoking

Ramírez-Sevilla C, Gómez-Lanza E, Puyol-Pallàs Josep-Miquel

Language: English
References: 20
Page:
PDF size: 285.13 Kb.


ABSTRACT

Introduction: This study analyzed patients with metabolic syndrome and smokers treated with MV140 vaccine to prevent recurrent UTI.
Material and methods: 342 patients with recurrent UTI received MV140 vaccine between 2017 and 2020 in Barcelona, Spain. Variables analyzed: number of UTI at 3 and 6 months after MV140, age, gender, diabetes mellitus, body mass index, hypertension, total cholesterol, HDL-cholesterol, triglycerides and smoking. Patients were divided in Group 1: metabolic syndrome (2 or more variables), Group 2: no metabolic syndrome (less than 2 variables). On the other hand, patients were classified into smokers and non-smokers.
Results: Mean age was 74, 82% were women. At the beginning, 88,9% had 3-5 UTI. Overall effectiveness with MV140 was 72.5% at 3 months and 56.2% at 6 months. Group 1 (36%) presented 0-1 UTI in 78.9% and 62.6% at 3 and 6 months. In Group 2 (64%) the results were 69% and 52.5%. Comparing both groups, no statistically significant differences were observed (p=0,25, p=0,26). Smokers had 77.4% and 61.3% at 3 and 6 months, and non-smokers had 69.3% and 52.7%. There were also no statistically significant differences (p = 0.5, p = 0.36). Group 1 and smoking (28,7%) had 82% at 3 months and 66.3% at 6 months. Group 2 and no smoking (71,3%) reached 60.3% and 52% at 3 and 6 months. There were no statistically significant differences between both groups.
Conclusions: The overall efficacy of MV140 was high and safe, without side effects. Patients with metabolic syndrome and smokers may benefit from this treatment


REFERENCES

  1. Foxman B. The epidemiology of urinary tractinfection. Nat Rev Urol. 2010;7(12):653–60.doi: https://doi.org/10.1038/nrurol.2010.190

  2. Bader MS, Loeb M, Brooks AA. An update onthe management of urinary tract infections inthe era of antimicrobial resistance. PostgraduateMedicine. 2017;129(2):242–58. doi: https://doi.org/10.1080/00325481.2017.1246055

  3. Chipa-Paucar Y. Comorbilidades asociadas ainfección de tracto urinario por Escherichia ColiBlee positivo del Hospital Vitarte. 2017 - 2018:Comorbidities associated with urinary tractinfection by positive escherichia coli blee, ininternal medicine service, Ate Vitarte Hospital.2017 - 2018. Revista de la Facultad de MedicinaHumana. 2019;19(3):1–1. doi: https://doi.org/10.25176/RFMH.v19i3.2162

  4. Barutell Rubio L. Paciente diabética coninfecciones urinarias de repetición. DiabetesPráctica. 2016;7(4):169–224

  5. Nitzan O, Elias M, Chazan B, Saliba W. Urinarytract infections in patients with type 2 diabetesmellitus: review of prevalence, diagnosis, andmanagement. DMSO. 2015;8:129–36. doi:https://doi.org/10.2147/DMSO.S51792

  6. Geerlings SE. Urinary tract infectionsin patients with diabetes mellitus:epidemiology, pathogenesis and treatment.International Journal of Antimicrobial Agents.2008;31(Supplement 1):54–7. doi: https://doi.org/10.1016/j.ijantimicag.2007.07.042

  7. Toledo J, Cubillo G, Gómez O. Asociación entreobesidad e infecciones: un estudio de cortetransversal. Revista Med. 2014;22(1):28–34.doi: https://doi.org/10.18359/rmed.1017

  8. Sinha MD, Postlethwaite RJ. Urinary tractinfections and the long-term risk of hypertension.Current Paediatrics. 2003;7(13):508–12. doi:https://doi.org/10.1016/j.cupe.2003.08.010

  9. Lorenzo-Gómez MF, Santos-Antunes MT,Nieto-Huertos A, Lorenzo-Gómez A, Marquez-Sanchez MT, Flores-Fraile MC, et al. Theinfluence of smoking on bacterial resistanceafter vaccine or antibiotic prophylaxis againstrecurrent urinary tract infections. Actas UrolEsp (Engl Ed). 2020;44(7):497–504. doi:https://doi.org/10.1016/j.acuro.2020.04.002

  10. Saklayen MG. The Global Epidemic of theMetabolic Syndrome. Curr Hypertens Rep.2018;20(2):12. doi: https://doi.org/10.1007/s11906-018-0812-z

  11. Pfau A, Sacks TG. Effective Prophylaxisfor Recurrent Urinary Tract Infectionsduring Pregnancy. Clinical InfectiousDiseases. 1992;14(4):810–4. doi: https://doi.org/10.1093/clinids/14.4.810

  12. Bauer HW, Rahlfs VW, Lauener PA, BlessmannGSS. Prevention of recurrent urinarytract infections with immuno-active E. colifractions: a meta-analysis of five placebocontrolleddouble-blind studies. Int J AntimicrobAgents. 2002;19(6):451–6. doi: https://doi.org/10.1016/S0924-8579(02)00106-1

  13. Naber KG, Cho Y-H, Matsumoto T, Schaeffer AJ.Immunoactive prophylaxis of recurrent urinarytract infections: a meta-analysis. Int J AntimicrobAgents. 2009;33(2):111–9. doi: https://doi.org/10.1016/j.ijantimicag.2008.08.011

  14. Bauer HW, Alloussi S, Egger G, BlümleinH-M, Cozma G, Schulman CC. A Long-Term, Multicenter, Double-Blind Study of anEscherichia Coli Extract (OM-89) in FemalePatients with Recurrent Urinary Tract Infections.European Urology. 2005;47(4):542–8. doi:https://doi.org/10.1016/j.eururo.2004.12.009

  15. Prieto L, Esteban M, Salinas J, Adot JM,Arlandis S, Peri L, et al. Documento de consensode la Asociación Española de Urología en elmanejo de las infecciones del tracto urinariorecurrentes no complicadas. Actas UrológicasEspañolas. 2015;39(6):339–48. doi: https://doi.org/10.1016/j.acuro.2014.10.003

  16. Prattley S, Geraghty R, Moore M, Somani BK.Role of Vaccines for Recurrent Urinary TractInfections: A Systematic Review. EuropeanUrology Focus. 2020;6(3):593–604. doi: https://doi.org/10.1016/j.euf.2019.11.002

  17. Tamadonfar KO, Omattage NS, SpauldingCN, Hultgren SJ. Reaching the End of theLine: Urinary Tract Infections. MicrobiologySpectrum. 2019;7(3):7.3.17. doi: https://doi.org/10.1128/microbiolspec.BAI-0014-2019

  18. González Pedraza Avilés A, Dávila MendozaR, Acevedo Giles O, Ramírez Martínez ME,Gilbaja Velázquez S, Valencia Gómez C, etal. Infección de las vías urinarias: prevalencia,sensibilidad antimicrobiana y factores de riesgoasociados en pacientes con diabetes mellitustipo 2. Revista Cubana de Endocrinología.2014;25(2):57–65.

  19. Nseir W, Farah R, Mahamid M, Sayed-Ahmad H, Mograbi J, Taha M, et al. Obesityand recurrent urinary tract infections inpremenopausal women: a retrospective study.Int J Infect Dis. 2015;41:32–5. doi: https://doi.org/10.1016/j.ijid.2015.10.014

  20. La Vecchia C, Negri E, D’Avanzo B, SavoldelliR, Franceschi S. Genital and urinary tractdiseases and bladder cancer. Cancer Res.1991;51(2):629–31.




2020     |     www.medigraphic.com